Abstract Details

Title Patient Preferences for Deep Brain Stimulation Products in Parkinson's Disease: What Really Matters to Them?

Topic Movement Disorders

Presentation(s) P5 - Poster Session 5 (11:45 AM-12:45 PM)

Poster/Presentation
Number 5-001

Objective To assess patient preferences in regards to choice of DBS product using qualitative methods.

Background The decision to undergo deep brain stimulation surgery for patients with Parkinson’s disease (PD) is complex and personal. In the United States, there are three manufacturers of DBS devices approved for PD by the Food and Drug Administration (FDA): Abbott, Boston Scientific, and Medtronic. Each of these DBS systems have different properties that impact an individual’s lifestyle. This is the first study to assess patient preferences in regards to choice of DBS product using qualitative methods.

Design/Methods Participants undergoing evaluation for DBS candidacy from January 2021 to early March 2021 were initially recruited from the University of Colorado Movement Disorders Center. A semi-structured interview was then conducted using an interview guide. All interviews were recorded and transcribed. Data were analyzed using the Rapid Approach to qualitative analysis. Recruitment is ongoing.

Results Eleven participants were enrolled in this study. The average age was 59.5 years and the average disease duration was 6.7 years. Many participants valued attributes of the batteries including the length of battery life, the rechargeability, and the size. Over half of the participants reported more programming options as an important factor. In this sample, 18% (2/11) selected Abbott, 82% (9/11) selected Boston Scientific, and none selected Medtronic. Participants reported receiving information on DBS products from a variety of sources.

Conclusions In this study, participants actively participated in selection of DBS products and reported a variety of common and individualized reasons for selection. The primary reasons involved features of battery and lead technology. As new technology emerges, participants’ reasons for selecting devices may change.

Authors/Disclosures
Michelle Fullard, MD (University of Colorado Anschutz) PRESENTER	Dr. Fullard has received research support from Davis Phinney Foundation. Dr. Fullard has received research support from Michael J. Fox Foundation. The institution of Dr. Fullard has received research support from NIH BIRCWH K12. Dr. Fullard has received research support from Lorna G. Moore Faculty Launch Fund.
Teresa Lee, MD (Advocate Aurora Health)	Dr. Lee has nothing to disclose.
	No disclosure on file
Steven Ojemann	The institution of Steven Ojemann has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alpha omega engineering. The institution of Steven Ojemann has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kenai Therapeutics. Steven Ojemann has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Insightec. Steven Ojemann has stock in Phasor inc.
Drew S. Kern, MD, FAAN (University of Colorado)	Dr. Kern has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. The institution of Dr. Kern has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Scientific. The institution of Dr. Kern has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Kern has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbott. The institution of Dr. Kern has received research support from Boston Scientific. The institution of Dr. Kern has received research support from AbbVie Pharmaceticals. Dr. Kern has received research support from Medtronic.

��ɫ��

��ɫ��